Skip to content
GLP-1 Clinics Nearby
Medication comparisonJuly 24, 2026 · 10 min read

Semaglutide vs. tirzepatide: compare the medication and the care plan

There is no universal winner. The useful comparison combines medical fit, exact product, tolerability, access, clinical support, and ongoing cost.

Edited by

· Co-founder & CTO, Savo Group

B.S. in Computer Science, Oregon State University · B.A. in Psychology, University of Washington, Seattle

Semaglutide versus tirzepatide treatment-plan comparison with a clinician

Current status

Two approved treatment families

Wegovy and Zepbound have weight-management indications; other brands containing these ingredients have different approved uses.

Semaglutide
GLP-1 receptor agonist
Tirzepatide
GIP and GLP-1 agonist
Decision owner
Patient and prescriber
At a glance

Semaglutide and tirzepatide side by side

This scan separates mechanism and product names from the individual medical and access decision.

Swipe horizontally to compare →

Semaglutide and tirzepatide side by side. This scan separates mechanism and product names from the individual medical and access decision.
Comparison pointSemaglutideTirzepatide
Receptor actionGLP-1 receptor agonistGIP and GLP-1 receptor agonist
Weight-management productWegovyZepbound
Diabetes product often discussedOzempicMounjaro
Individual decision still needsHistory, label review, tolerability, access, and follow-upHistory, label review, tolerability, access, and follow-up

Table source:FDA Wegovy and Zepbound prescribing information

01

The first difference is the mechanism

Semaglutide is a GLP-1 receptor agonist. Tirzepatide activates both GIP and GLP-1 receptors. Their weight-management products—Wegovy and Zepbound—have separate labels, evidence, dosing instructions, warnings, and approved uses.

Average results reported in different trials do not predict one person’s response and are not a substitute for a head-to-head discussion with a prescriber. Medical history, current medicines, prior experience, side effects, coverage, supply, and goals all affect the practical choice.

02

Compare the product—not only the molecule

Wegovy contains semaglutide and Zepbound contains tirzepatide. Ozempic and Mounjaro contain those same respective active ingredients but have different FDA-approved indications. Compounded preparations are not FDA-approved generic versions of these brands.

Before comparing price, identify the exact product each clinic or online program offers. Otherwise two offers that appear similar may represent different formulations, pharmacy arrangements, and regulatory status.

03

Both comparisons need a side-effect and monitoring plan

The current prescribing information for both products includes gastrointestinal adverse reactions among common effects and contains additional warnings and contraindications. The details and frequencies belong in the respective labels.

Ask how the program responds to symptoms, whether live clinical contact is available, and what happens if treatment is paused or changed. A refill pipeline without a clear clinical contact path is not the same as continuing care.

04

The cheapest headline can become the more expensive program

Compare the total after the introductory period: clinical membership, medication, lab work, shipping, follow-up, dose-related changes, insurance assistance, and any required commitment. Write those components beside each other before deciding.

If one offer is compounded and another is an FDA-approved brand, label that difference explicitly. Do not treat them as equivalent products in a price table.

  • Exact product and formulation
  • FDA-approved use or compounded status
  • Named prescribing organization
  • Complete ongoing price
  • Follow-up and urgent-contact process
  • Cancellation and medication-change policy
Medication selection is individualized. This comparison is designed to improve the questions you bring to a prescriber, not decide which product you should take.

Common questions

Answers to clarify the comparison

Which causes more weight loss: semaglutide or tirzepatide?
Trial averages are not individual predictions, and studies can differ in design and population. Discuss the current evidence, product labels, tolerability, access, and your health history with a prescriber.
Can I switch from semaglutide to tirzepatide?
Switching requires an individualized prescribing plan. Do not overlap, stop, or change treatment based on a generic schedule from the web.
Are compounded versions equivalent to Wegovy or Zepbound?
No. Compounded drugs are not FDA-approved generic versions, and FDA does not review them for safety, effectiveness, or quality before marketing.

Primary sources

Read the official material behind this page

Health information is educational and does not diagnose, determine eligibility, or replace product labeling and care from a qualified professional.